Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EBS stock price vs SRPT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SRPT's multiple
Needs SRPT P/E.
Implied fair value · at EBS's multiple
Needs Annual EPS is negative, EBS P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EMERGENT BIOSOLUTIONS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
SAREPTA THERAPEUTICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
EBS vs MRNA
SIGA TECHNOLOGIES INC
EBS vs SIGA
Amphastar Pharmaceuticals, Inc.
EBS vs AMPH
CATALYST PHARMACEUTICALS, INC.
EBS vs CPRX
Organon & Co.
EBS vs OGN
PERRIGO Co plc
EBS vs PRGO
AMGEN INC
EBS vs AMGN
BIOMARIN PHARMACEUTICAL INC
EBS vs BMRN
Replimune Group, Inc.
EBS vs REPL
PTC THERAPEUTICS, INC.
EBS vs PTCT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EBS can stabilize revenue declines while preserving its current profitability, then the stock looks attractive versus SRPT-implied price because EBS is already profitable and trades at a lower P/S multiple than SRPT.
EBS trades at $8.28 versus a SRPT-implied $13.29, implying about 60.5% upside on the provided P/S framework. The valuation gap is driven by EBS’s much stronger current profitability versus SRPT, but the market is also discounting EBS for declining revenue and balance-sheet risk.
Supporting Metrics
